ios H4
Alternative Names: ios-H4Latest Information Update: 28 Sep 2024
At a glance
- Originator ImmunOs Therapeutics
- Class Antineoplastics; Immunotherapies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Cancer in Switzerland (Parenteral)
- 25 Aug 2020 ios H4 is available for licensing as of 25 Aug 2020. http://www.immunostherapeutics.com/
- 25 Aug 2020 Early research in Cancer in Switzerland (Parenteral), prior to August 2020 (ImmunOs Therapeutics pipeline, August 2020)